These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22291080)

  • 21. Gallium nitrate in advanced soft tissue and bone sarcomas: a Southwest Oncology Group Study.
    Saiki JH; Baker LH; Stephens RL; Fabian CJ; Kraut EH; Fletcher WS
    Cancer Treat Rep; 1982 Aug; 66(8):1673-4. PubMed ID: 7105060
    [No Abstract]   [Full Text] [Related]  

  • 22. Emerging therapeutic targets for synovial sarcoma.
    Palmerini E; Paioli A; Ferrari S
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):791-806. PubMed ID: 24661286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTOR signaling and drug development in cancer.
    Dancey J
    Nat Rev Clin Oncol; 2010 Apr; 7(4):209-19. PubMed ID: 20234352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promising advances in the treatment of malignant pancreatic endocrine tumors.
    Jensen RT; Delle Fave G
    N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243
    [No Abstract]   [Full Text] [Related]  

  • 25. New therapeutics for soft-tissue sarcomas in adults.
    von Mehren M
    Oncology (Williston Park); 2007 Jan; 21(1):123-6. PubMed ID: 17313160
    [No Abstract]   [Full Text] [Related]  

  • 26. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
    Liakakos T; Roukos DH
    Future Oncol; 2011 Sep; 7(9):1025-9. PubMed ID: 21919689
    [No Abstract]   [Full Text] [Related]  

  • 27. Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33.
    Procopio G; Verzoni E; De Braud F
    Eur Urol; 2012 Jul; 62(1):e5-6; author reply e7-8. PubMed ID: 22487015
    [No Abstract]   [Full Text] [Related]  

  • 28. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
    Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
    Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.
    Roca S; Quivy A; Gross-Goupil M; Bernhard JC; De Clermont H; Ravaud A
    Acta Oncol; 2011 Oct; 50(7):1135-6. PubMed ID: 21726178
    [No Abstract]   [Full Text] [Related]  

  • 30. Use of chemotherapy for patients with bone and soft-tissue sarcomas.
    Wesolowski R; Budd GT
    Cleve Clin J Med; 2010 Mar; 77 Suppl 1():S23-6. PubMed ID: 20179184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus in HR-positive advanced breast cancer.
    Tartarone A; Lerose R; Aieta M
    N Engl J Med; 2012 May; 366(18):1739; author reply 1739-40. PubMed ID: 22551140
    [No Abstract]   [Full Text] [Related]  

  • 32. Everolimus in HR-positive advanced breast cancer.
    Massarweh S; Croley J; Weiss H
    N Engl J Med; 2012 May; 366(18):1738-9; author reply 1739-40. PubMed ID: 22551139
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
    Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
    Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.
    Ekshyyan O; Mills GM; Lian T; Amirghahari N; Rong X; Lowery-Nordberg M; Abreo F; Veillon DM; Caldito G; Speicher L; Glass J; Nathan CO
    Head Neck; 2010 Dec; 32(12):1619-28. PubMed ID: 20222045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intestinal Kaposi sarcoma in a lung transplant recipient: therapy with mammalian target of rapamycin inhibitor and immunosuppression reduction.
    Lund MB; Paulsen V; Aukrust P
    J Heart Lung Transplant; 2013 Mar; 32(3):376-7. PubMed ID: 23305694
    [No Abstract]   [Full Text] [Related]  

  • 36. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
    Wacheck V
    Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
    [No Abstract]   [Full Text] [Related]  

  • 37. Generic sirolimus: a future opportunity to decrease the cost of oncology care?
    Baker LH
    Clin Adv Hematol Oncol; 2013 Feb; 11(2):102-3. PubMed ID: 23598911
    [No Abstract]   [Full Text] [Related]  

  • 38. The Current Landscape of Early Drug Development for Patients With Sarcoma.
    Wilky BA; Jones RL; Keedy VL
    Am Soc Clin Oncol Educ Book; 2017; 37():807-810. PubMed ID: 28561654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temsirolimus for metastatic desmoplastic small round cell tumor.
    Thijs AM; van der Graaf WT; van Herpen CM
    Pediatr Blood Cancer; 2010 Dec; 55(7):1431-2. PubMed ID: 20730888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
    Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
    Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.